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Abstract
G protein-coupled receptors (GPCRs) modulate cytoplasmic signalling in response to extracellular
stimuli, and are important therapeutic targets in a wide range of diseases. Structure determination
of GPCRs in all activation states is important to elucidate the precise mechanism of signal trans-
duction and to facilitate optimal drug design. However, due to their inherent instability, crystallisa-
tion of GPCRs in complex with cytoplasmic signalling proteins, such as heterotrimeric G proteins
and β-arrestins, has proved challenging. Here, we describe the design of a minimal G protein,
mini-Gs, which is composed solely of the GTPase domain from the adenylate cyclase stimulating
G protein Gs. Mini-Gs is a small, soluble protein, which efﬁciently couples GPCRs in the absence of
Gβγ subunits. We engineered mini-Gs, using rational design mutagenesis, to form a stable com-
plex with detergent-solubilised β1-adrenergic receptor (β1AR). Mini G proteins induce similar
pharmacological and structural changes in GPCRs as heterotrimeric G proteins, but eliminate
many of the problems associated with crystallisation of these complexes, speciﬁcally their large
size, conformational dynamics and instability in detergent. They are therefore novel tools, which
will facilitate the biochemical and structural characterisation of GPCRs in their active
conformation.
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Introduction
G protein-coupled receptors (GPCRs) modulate cytoplasmic signal-
ling, through heterotrimeric G proteins and β-arrestins, in response
to extracellular stimuli, such as hormones and neurotransmitters
(Rosenbaum et al., 2009). The central role of GPCRs in regulating
cellular responses makes them an important therapeutic target
(Lagerstrom and Schioth, 2008). GPCRs adopt different conform-
ational states in response to binding different classes of ligand and
coupling to cytoplasmic signalling proteins. Therefore, structure
determination of GPCRs in all activation states is important to
decipher the molecular mechanisms of signal transduction, and to
facilitate optimal drug design.
Heterotrimeric G proteins are composed of α, β and γ subunits.
Gα consists of a GTPase domain (GαGTPase), which is analogous
to members of the small GTPase superfamily of proteins, and an α-
helical domain (GαAH), which is unique to heterotrimeric G pro-
teins (Sprang, 1997). In the inactive, GDP-bound state, Gα binds
Gβγ, forming a heterotrimer with low basal nucleotide exchange
activity (Higashijima et al., 1987). The trimer is anchored to the cell
membrane, through lipid modiﬁcations of both Gα and Gγ (Spiegel
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et al., 1991). GPCRs catalyse rapid nucleotide exchange on hetero-
trimeric G proteins, but only weakly activate the isolated α subunit
(Herrmann et al., 2006; Phillips et al., 1992).
Agonist binding to a GPCR promotes its transition to a structural
state that can efﬁciently interact with heterotrimeric G proteins
(Lebon et al., 2011b; Rasmussen et al., 2011b; Rosenbaum et al.,
2011; Xu et al., 2011). The agonist-bound receptor engages the C-
terminal region of Gα (Hamm et al., 1988), initiating a rotation and
displacement of the α5 helix (Oldham et al., 2006). This ultimately
destabilises the nucleotide-binding pocket and the GαGTPase–GαAH
domain interface, allowing GDP to dissociate (Alexander et al., 2014;
Dror et al., 2015; Flock et al., 2015; Kaya et al., 2014; Sun et al.,
2015; Van Eps et al., 2011). The resulting nucleotide-free ternary
complex displays large, mutually induced structural changes in both
the receptor and G protein (Rasmussen, et al., 2011b), and is often
characterised by increased agonist binding afﬁnity of the receptor
(Delean et al., 1980). This complex can be trapped in the absence of
guanine nucleotides (Bornancin et al., 1989), but is extremely short-
lived in vivo due to rapid binding of GTP to Gα (Vuong et al., 1984).
GTP binding triggers dissociation of the G protein from the receptor
(Kuhn, 1981) and separation of Gα from Gβγ (Fung et al., 1981).
GPCR–G protein complexes are difﬁcult targets for structural
studies due to their large size, conformational dynamics, and
instability in detergent. To date, only a single structure of a GPCR–
G protein complex has been reported, namely the β2-adrenergic
receptor (β2AR) bound to the adenylate cyclase stimulating G pro-
tein Gs (Rasmussen et al., 2011b). This structure provided the ﬁrst
atomic resolution insight into the organisation of the ternary com-
plex, but further structures are required to fully decipher the
molecular mechanisms of signal transduction and the speciﬁcity for
G protein coupling. Given the difﬁculties in crystallising GPCR–G
protein complexes, novel tools are needed to facilitate their high-
throughput crystallisation.
Here, we report the design of a minimal G protein, termed mini-
Gs, which is composed solely of the GαGTPase domain from Gs.
Mini-Gs closely mimics the pharmacological and structural changes
induced in GPCRs by heterotrimeric Gs. It is therefore a novel tool,
which will facilitate the characterisation of GPCRs in their active con-
formation, and has allowed the structure determination of the adeno-
sine A2A receptor in the fully active state (Carpenter et al., 2016).
Materials and Methods
Cloning
Details of G protein, β1AR and mini-Gs constructs used in this work are
provided in Supplementary Tables SI–SIII, respectively. All G proteins
used in this study were mutated to remove sites of lipid modiﬁcation. G
protein cDNAs were cloned into the transfer vector pBacPAK8
(Clontech), and baculoviruses were prepared using the ﬂashBAC
ULTRA system (Oxford Expression Technologies). Synthetic genes
(Integrated DNA Technologies) for Nb80 (Rasmussen et al., 2011a)
and Nb35 (Westﬁeld et al., 2011) were cloned into pET26b (Novagen)
for periplasmic expression in Escherichia coli. Mini-Gs constructs,
which were derived from the long isoform of the human Gαs gene, were
cloned into the pET15b vector (Novagen) for expression in E. coli.
Expression and puriﬁcation of β1AR
β1AR constructs were expressed in insect cells using the baculovirus
expression system, and puriﬁed as described previously (Warne
et al., 2003; Warne et al., 2011; Warne et al., 2009).
Baculovirus expression of G proteins
Trichoplusia ni cells (Expression Systems) were grown in ESF921
serum-free media (Expression Systems) in 5 L optimum growth
ﬂasks (Thompson Instrument Company). Immediately before
infection, heat-inactivated foetal bovine serum (Sigma) was added
to a ﬁnal concentration of 5%. Cells were infected with third pas-
sage virus at a ﬁnal concentration of 3%. In the case of co-
infection with multiple viruses (for heterotrimeric Gs or Gβγ) each
virus was added to a ﬁnal concentration of 3%. The ﬁnal volume
of culture was 3 L per ﬂask and the ﬁnal cell density was 3 × 106
cells/ml. Cells were harvested 48 h post-infection by centrifuga-
tion at 5000 g for 5 mins, ﬂash-frozen in liquid nitrogen and
stored at −80°C.
Protein puriﬁcation
Details of G protein, nanobody and mini-Gs puriﬁcations are pro-
vided in the Supplementary material.
Saturation binding assay
Insect cell membranes containing β1AR were resuspended in assay
buffer (20mM HEPES pH 7.5, 100mM NaCl). The sample was ali-
quoted and [3H]-dihydroalprenolol was added (to give ﬁnal concen-
trations in the range of 0.25 nM to 256 nM), alprenolol was added
to the negative control (1 mM ﬁnal concentration). Samples were
incubated at 20°C for 2 h, before ﬁltering through 96-well glass ﬁbre
ﬁlter plates (Merck Millipore) and washing with ice-cold assay buf-
fer. Radioactivity was quantiﬁed by scintillation counting and
apparent Kd values were determined using GraphPad Prism version
5.0 (GraphPad Software, San Diego, CA).
Competition binding assay
Insect cell membranes containing β1AR were resuspended in assay
buffer (25mM HEPES pH 7.5, 100mM NaCl, 1 mM MgCl2, 1 mM
ascorbate). The sample was aliquoted and binding partner (25 μM
ﬁnal concentration), isoprenaline (ﬁnal concentrations in the range
of 1 pM–100mM) and apyrase (0.1 U/ml ﬁnal concentration) were
added. Alprenolol was added to the negative control (100 μM ﬁnal
concentration). Samples were incubated at 20°C for 1.5 h, before
adding [3H]-dihydroalprenolol (5 or 20 nM ﬁnal concentrations
for β1ARΔNC or β1AR-84, respectively). Samples were incubated at
20°C for 1.5 h, before ﬁltering through 96-well glass ﬁbre ﬁlter
plates and washing with ice-cold assay buffer. Radioactivity was
quantiﬁed by scintillation counting and Ki values were determined
using GraphPad Prism version 5.0.
Competition binding assays using detergent-solubilised β1AR-84
were performed using a similar protocol, except: all steps were per-
formed at 4°C; membranes were solubilised with dodecyl maltoside
(DDM; 0.1% ﬁnal concentration) for 30min, prior to addition of
binding partner and ligands; separation of bound from free ligand
(by gel ﬁltration) was performed exactly as described in the thermo-
stability assay protocol (below).
Thermostability measurement of β1ARΔNC–mini-Gs
complexes
Thermostability assays were performed using a modiﬁed version of
previously described methods (Lebon et al., 2011a; Serrano-Vega
et al., 2008). Insect cell membranes containing β1ARΔNC were resus-
pended in assay buffer (25mM HEPES pH 7.5, 400mM NaCl,
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1mM MgCl2, 1 mM ascorbate, 0.1% BSA, 0.004% bacitracin). The
sample was aliquoted and binding partner (25 μM ﬁnal concentra-
tion), 3H-norepinephrine (200 nM ﬁnal concentration) and apyrase
(0.1 U/ml ﬁnal concentration) were added. Norepinephrine was
added to the negative control (200 μM ﬁnal concentration). Samples
were incubated at 4°C for 1 h, before solubilisation with detergent
for 1 h on ice. The detergents dodecyl maltoside (DDM), decyl mal-
toside (DM), nonyl glucoside (NG) or octyl glucoside (OG) were
used at ﬁnal concentrations of 0.1, 0.13, 0.3 or 0.8%, respectively.
Samples were heated to different temperatures (between 4 and 50°
C) for exactly 30min, followed by quenching on ice for 30min.
Samples were separated by gel ﬁltration through Toyopearl HW-
40F resin packed in a 96-well ﬁlter plate (Merck Millipore).
Radioactivity was quantiﬁed by scintillation counting and apparent
melting temperature (Tm) values were determined using GraphPad
Prism version 5.0.
Thermostability measurement of GDP-bound mini-Gs
mutants by differential scanning ﬂuorimetry
Differential scanning ﬂuorimetry (DSF) was performed essentially as
described previously (Niesen et al., 2007). Mini-Gs mutants (30 μg)
were diluted with assay buffer (10mM HEPES pH 7.5, 100mM
NaCl, 1 mM MgCl2, 1 mM GDP, 2mM DTT). SYPRO-orange was
added to give a ﬁnal concentration of ×2. Thermostability measure-
ments were performed using a Rotor-Gene Q (Qiagen). Samples
were equilibrated for 90 s at 25°C before ramping from 25 to 99°C
at 4 s/°C. The apparent melting temperature (Tm), corresponding to
the inﬂection point of the curve, was derived from analysis using the
Rotor-Gene Q software.
Gel ﬁltration analysis of mini G protein complexes
The mini-Gs–βγ complex was prepared using mini-Gs399, a con-
struct in which the N-terminal residues 6–25 were replaced and
the L272D mutation was reversed (Supplementary Table SIII).
Puriﬁed mini-Gs399 was mixed with non-lipidated Gβ1γ2 dimer
in an equimolar ratio and incubated on ice for 4 h. The sample
was loaded onto a Superdex-200 10/300 gel ﬁltration column
(GE healthcare), equilibrated with gel ﬁltration buffer (10 mM
HEPES pH 7.5, 100 mM NaCl, 1 mM MgCl2, 1 μM GDP,
0.1 mM TCEP).
The β1AR–mini-Gs complex was prepared using β1ARΔNC puri-
ﬁed in lauryl maltose neopentyl glycol (LMNG) detergent. Puriﬁed
β1ARΔNC was mixed with a 1.2-fold molar excess of mini-Gs393
and incubated on ice for 4 h. The sample was loaded onto a
Superdex-200 10/300 gel ﬁltration column, equilibrated with gel ﬁl-
tration buffer (10mM HEPES pH 7.5, 100mM NaCl, 1mM
MgCl2, 1 μM ascorbic acid, 1 μM isoprenaline, 0.002% LMNG).
Peak fractions were analysed by SDS-PAGE on a 4–20% Tris-
glycine gel (Thermo Fisher).
The gel ﬁltration column was calibrated using molecular weight
standards (Sigma), and the apparent molecular weight of samples
was calculated using the calibration curve shown in Supplementary
Fig. S9.
Statistical analysis
Unpaired, two-tailed t-tests were used to compare two data sets, and
P values are quoted in the text.
Results
Strategy to develop a minimal G protein
The aim of this work was to isolate the minimum component of Gs
that could be used to crystallise native-like GPCR–G protein com-
plexes. The molecular weight of Gs is 90 kDa, however, the β2AR–
Gs complex (Rasmussen et al., 2011b) revealed that more than 97%
of direct contacts between the G protein and receptor are mediated
by the 27 kDaGαGTPase domain (Fig. 1a). We hypothesised that
this domain would be sufﬁcient to stabilise GPCRs in their fully
active state, i.e. the conformation adopted by β2AR in the β2AR–Gs
complex (Rasmussen et al., 2011b), and it was therefore used as the
starting point to engineer a minimal G protein (mini-Gs; Fig. 1b).
Three binding partners were used as controls during this work:
Nb80, a nanobody that binds to β2AR and induces a comparable
shift in agonist binding afﬁnity to heterotrimeric Gs (Rasmussen
et al., 2011a); soluble heterotrimeric Gs that was mutated to remove
all potential lipidation sites, referred to herein as Gs (Supplementary
Table SI); and Nb35, a nanobody that stabilises Gs in its GPCR-
bound conformation (Westﬁeld et al., 2011). Gs was either used
alone (referred to as Gs) or in the presence of Nb35 (referred to as
Gs–Nb35). As active state structures of β2AR bound to either Nb80
or Gs–Nb35 have been determined (Rasmussen et al., 2011a,
2011b), the stability and pharmacological activity of an engineered
mini-Gs should, at a minimum, reﬂect the analogous properties of
these binding partners.
The β1-adrenergic receptor (β1AR) was used as a model GPCR in
the development of mini-Gs. Both β1AR and β2AR are able to bind
Gs and Nb80 and exhibit a signiﬁcant increase in agonist binding
afﬁnity. Either receptor could have been used for the development of
mini-Gs, but because our laboratory has developed a large number
of thermostabilised β1AR variants (Miller and Tate, 2011; Serrano-
Vega et al., 2008), we chose to work with β1AR. We did not use the
adenosine A2A receptor for the development of mini-Gs, because
(b)(a)
β2AR
    Gα
GTPase
    GαAH
Nb35
Gβ1
Gγ2
Membrane
    GPCR
    Mini-Gs
Fig. 1 Design of a minimal G protein. (a) Crystal structure of the β2AR–Gs
complex (PDB code 3SN6; Rasmussen et al., 2011b). The intracellular compo-
nent of this complex, which is composed of Gαs, Gβ1, Gγ2 and Nb35, totals
over 100 kDa in molecular weight. However, over 97% of direct contacts
(3.9 Å cut-off) between β2AR and Gs are formed by the GαGTPase domain
(cyan). Residues from Gs that form contacts with β2AR are shown as spheres.
(b) Model of the proposed complex between a GPCR and mini-Gs (isolated
GαGTPase domain). The intracellular component of this complex is a single
protein with a molecular weight of approximately 27 kDa. Figures were pre-
pared using PyMOL (The PyMOL Molecular Graphics System, Version 1.7.4
Schrödinger, LLC)
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there is only a small increase in agonist afﬁnity upon binding a G
protein (Carpenter et al., 2016).
To be most useful for the characterisation and structure determin-
ation of GPCRs in their active state, mini-Gs needed to fulﬁl a number
of criteria. Mini-Gs should be stable enough in its basal conformation
to allow high-yield expression and puriﬁcation, promote the transi-
tion of β1AR to the high-afﬁnity agonist-bound state, and form a
stable complex with detergent-solubilised β1AR. The development of
mini-Gs involved a number of key steps, some of which only became
apparent as the work progressed: (i) development of a sensitive assay
to detect G protein coupling to β1AR; (ii) isolation of the GαGTPase
domain (mini-Gs) and demonstration of binding to β1AR; (iii) thermo-
stabilisation of the β1AR–mini-Gs complex in membranes; (iv) ther-
mostabilisation of the β1AR–mini-Gs complex in detergent; and (v)
validation of the ﬁnal mini-Gs construct. Details of each of these steps
are given under the corresponding subheadings later.
Development of a sensitive assay to detect G protein
coupling to β1AR
A sensitive competition binding assay was developed that could
detect the interaction of different binding partners with β1AR, by
measuring the afﬁnity of agonist binding to the receptor. A heterol-
ogous competition format was used to determine the agonist binding
afﬁnity (Ki) of β1AR by measuring binding of the antagonist 3H-
dihydroalprenolol (3H-DHA; Supplementary Fig. S1) in the presence
of increasing concentrations of the agonist isoprenaline. The concen-
tration of binding proteins used in the assays was standardised to
25 μM, which was approximately 30-fold above the equilibrium dis-
sociation constant (KD) for Nb80 binding to β1AR (Miller-Gallacher
et al., 2014). Initially, we used a truncated form of turkey β1AR
(Warne et al., 2003), which was designated β1ARΔNC
(Supplementary Table SII). This construct did not contain any ther-
mostabilising mutations, and behaved identically to full-length
receptor in cell-signalling assays (Baker et al., 2011), despite con-
taining truncations of disordered regions in the N-terminus and C-
terminus. The Ki for isoprenaline binding to β1ARΔNC was
40 ± 0 nM in the absence of a binding partner, which shifted to
5.8 ± 0.8 nM, 17 ± 2 nM or 6.8 ± 0.6 nM in response to Nb80, Gs
or Gs–Nb35, respectively (Supplementary Fig. S2). The shift in iso-
prenaline Ki upon G protein binding to β1ARΔNC was relatively
small, which was unsuitable for detecting potentially small changes
elicited upon binding of unstable G protein derivatives during the
development of mini-Gs. We therefore used a minimally thermosta-
bilised β1AR construct (β1AR-84; Supplementary Table SII), which
contained four mutations that increased the stability preferentially
of the inactive state of the receptor (Miller-Gallacher et al., 2014;
Warne et al., 2011), in addition to the truncations at the N-terminus
and C-terminus. β1AR-84 had a lower afﬁnity for isoprenaline (Ki of
2.6 ± 0.3 μM) in its uncoupled state than β1ARΔNC, but showed a
larger shift in agonist binding afﬁnity when coupled to either Nb80,
Gs or Gs–Nb35 (Ki of 28 ± 1 nM, 271 ± 54 nM or 16 ± 4 nM,
respectively; Table I and Supplementary Fig. S2). The competition
binding data ﬁtted best to single-site binding parameters. Therefore,
the partial shift in isoprenaline Ki observed for some binding part-
ners most likely reﬂected incomplete stabilisation of the high-afﬁnity
agonist-bound state, rather than indicating partial coupling or
mixed receptor populations. Although Gs was able to couple β1AR,
Nb35 was required to stabilise the Gs complex, resulting in β1AR–
Gs–Nb35 complexes with similar afﬁnity for isoprenaline compared
to the β1AR–Nb80 complexes (Table I and Supplementary Fig. S2).
The competition binding assay using β1AR-84 showed a 162-fold
increase in isoprenaline afﬁnity upon Gs–Nb35 coupling to the
receptor, which was far larger than the 6-fold shift in afﬁnity
induced by Gs–Nb35 binding to β1ARΔNC. We therefore used β1AR-
84 in all subsequent competition binding assays during the develop-
ment of mini-Gs.
Isolation of the Gαs GTPase domain and measuring
binding to β1AR-84
The GαGTPase domain from Gαs had previously been expressed as
an isolated protein, in order to determine its role in guanine nucleo-
tide binding and hydrolysis (Markby et al., 1993), but its ability to
couple to GPCRs had never been investigated. We isolated the
GTPase domain by replacing the sequence corresponding to GαAH
with a short glycine linker (Supplementary Table SIII). This con-
struct, mini-Gs77, expressed poorly in E. coli and could not be puri-
ﬁed to homogeneity, indicating that it was very unstable.
Nevertheless, a small amount of partially pure protein could be pre-
pared (Supplementary Fig. S3), and was tested for its ability to cou-
ple β1AR-84 (at 20°C) in either the presence or absence of Gβγ–
Nb35. No signiﬁcant shift in the isoprenaline Ki of β1AR-84
(2.6 ± 0.3 μM) was observed in the presence of mini-Gs77
(1.9 ± 0.2 μM; P = 0.254), but mini-Gs77–Gβγ–Nb35 induced a
large shift in isoprenaline afﬁnity to 3.6 ± 0.8 nM (P = 0.004;
Table I and Supplementary Fig. S2). Thus partially puriﬁed mini-
Gs77 was functional, but the data also suggested that it was unable
to couple β1AR-84 in the absence of Gβγ when assayed at 20°C. In
contrast, when the assay was performed at 4°C mini-Gs77 induced a
signiﬁcant shift in isoprenaline Ki from 2.1 ± 0.2 μM for uncoupled
β1AR-84 (at 4°C) to 99 ± 12 nM (P < 0.001; Table I and
Supplementary Fig. S2). This demonstrated that the isolated
GαGTPase domain (mini-Gs77) could couple to β1AR-84 in the
absence of Gβγ, but suggested that the thermostability of the
GαGTPase domain was a limiting factor in its ability to stabilise the
high-afﬁnity agonist-bound state of the receptor.
Thermostabilisation of the β1AR–mini-Gs complex in
membranes
Rational design mutagenesis was employed to thermostabilise mini-
Gs in complex with membrane-embedded β1AR. Mutations were
designed based on structural alignments (Fig. 2a and Supplementary
Fig. S4) between Gαs (Sunahara et al., 1997) and Arl2 (Hanzal-
Bayer et al., 2002); Arl2 is the small GTPase with the greatest struc-
tural similarity to Gαs. This initial mutagenic screen primarily tar-
geted regions of Gαs that were close to the GαAH domain interface
or that were known to be conformationally dynamic. Mutants were
screened using the competition binding assay at both 4 and 20°C.
Due to the low, and variable expression level of the mutants, it was
not easy to standardise the concentration of mini-Gs mutants used
in the assays. Therefore, the total mini-Gs puriﬁed from 1 L of E.
coli culture was used per competition curve (Table I).
Approximately 100 mutants were tested during this initial screen.
Mutations that shifted the isoprenaline Ki of β1AR-84 more than 2-
fold compared to the parental mini-Gs construct (mini-Gs77) at
either temperature were classed as positive. A total of 16 positive
mutations, covering 12 unique positions were identiﬁed (Table I).
Some of the single mini-Gs mutants produced a near maximal
shift in the agonist binding afﬁnity of β1AR-84 in the competition
binding assay, therefore, mutation combinations could not be
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reliably tested using this assay, as further small increases in agonist
afﬁnity would be difﬁcult to accurately measure. Instead, the muta-
tion combinations were tested in complex with detergent-solubilised
β1ARΔNC using a thermostability (Tm) assay (Table II). The agonist
3H-norepinephrine (3H-NE) was used in the Tm assay, however due
to the high background signal associated with this ligand, a max-
imum concentration of 200 nM could be used. This was approxi-
mately equal to the Ki of uncoupled β1ARΔNC, but approximately
250-fold above the Ki of β1ARΔNC complexed with Nb80 or Gs–
Nb35 (Supplementary Fig. S5). Therefore, apparent Tm values
quoted for uncoupled β1ARΔNC are under non-saturated agonist
conditions, but β1ARΔNC complexes, which have higher agonist
binding afﬁnity, are under agonist-saturated conditions.
A new parental construct (mini-Gs161), was used to test combi-
nations of the mutations; mini-Gs161 contained a larger deletion
encompassing GαAH with a slightly longer linker than in mini-Gs77
(Supplementary Table SIII). The A249D mutant (mini-Gs162) pro-
duced the largest shift in the agonist binding afﬁnity of membrane-
embedded β1AR-84 in the competition binding assay, however, in
detergent the β1ARΔNC–mini-Gs162 complex had an apparent Tm of
25.1°C (Table II), which was lower than that of uncoupled of
β1ARΔNC (25.9°C). Addition of the switch III deletion, which
induced the second largest shift in the agonist binding afﬁnity of
membrane-embedded β1AR-84, to make a double mutant (mini-
Gs164), increased the apparent Tm of the complex to 28.6°C
(Table II). However, this was still lower than that of either
β1ARΔNC–Nb80 or β1ARΔNC–Gs–Nb35, by 3.4 and 7.2°C, respect-
ively (Table II). Addition of other mutations that were classed as
positive in the competition binding assay failed to further increase
the apparent Tm of the β1ARΔNC–mini-Gs complex (examples shown
in Table II), indicating that the complex was particularly unstable in
detergent. This was conﬁrmed by the observation that mini-Gs
mutants were unable to shift the agonist binding afﬁnity of
detergent-solubilised β1AR-84 to the same degree as that of
membrane-embedded β1AR-84 in competition binding assays
(results not shown). Despite the fact that they did not further stabil-
ise the β1ARΔNC–mini-Gs complex in detergent, four additional
mutations (G49D, E50N, S252D and L272D) were added to mini-
Gs164 to produce the construct mini-Gs183 (Table II). These muta-
tions were utilised because they all individually increased the iso-
prenaline Ki of membrane-embedded β1AR-84 (Table I). They also
increased the stability of the basal GDP-bound state mini-Gs183 by
6°C compared to mini-Gs164 (Table II and Supplementary Fig. S6),
as assessed by differential scanning ﬂuorimetry.
Five of the six mutations that were combined in mini-Gs183
were clustered around the nucleotide-binding pocket and phosphate-
binding loop (P-loop; Fig. 2a). The A249D mutation was designed
to interact with Lys293 and Ser251, in order to stabilise the base of
the nucleotide-binding pocket. Deletion of switch III was intended to
stabilise mini-Gs, by replacing this ﬂexible loop with the deﬁned sec-
ondary structure elements (α-helix, 310-helix and β-turn) found in
Arl2 (Hanzal-Bayer et al., 2002). The S252D mutation was also
Table I. β1AR-84 competition binding data
Binding partner Mutation CGN codea β1AR-84 isoprenaline Ki (nM) Effect on expression
4°C 20°C
None n.a.b n.a. 2100 ± 180 (n = 12) 2600 ± 270 (n = 15) n.a.
Nb80 n.a. n.a. n.d.c 28 ± 1 (n = 2) n.a.
Gs n.a. n.a. 420 ± 80 (n = 2) 271 ± 54 (n = 2) n.a.
Gs–Nb35 n.a. n.a. n.d. 16 ± 4 (n = 3) n.a.
Mini-Gs77 Parental n.a. 99 ± 12 (n = 4) 1900 ± 230 (n = 3) n.a.
H41I 41G.S1.2 32 390 =
H41V 41G.S1.2 51 490 =
A48L 48G.s1h1.2 43 170 =
G49D 49G.s1h1.3 25 280 =
E50N 50G.s1h1.4 37 720 =
R201A 201G.hfs2.2 31 1480 −
G226A 227G.s3h2.2 86 820 =
227–230 subd 227G.s3h2.3 23 530 =
E230A 230G.H2.3 51 540 −
A249D 249G.S4.7 10 35 +
A249E 249G.S4.7 70 390 =
S252D 252G.s4h3.3 14 94 +
S252E 252G.s4h3.3 38 380 +
255–264 dele 254G.s4h3.5 21 20 +
L272D 272G.H3.8 7 310 =
L272E 272G.H3.8 28 750 =
Competition binding data showing the isoprenaline Ki of β1AR-84 in the presence of different binding partners. Data are from a single experiment performed
in duplicate unless otherwise stated; where two or more independent experiments were performed, data represent mean ± SEM, from the number (n) of independ-
ent experiments performed in duplicate. The effect of mutations on the expression level of mini-Gs was estimated from SDS-PAGE gels. Expression levels are
described as being equal to (=), more than 2-fold lower than (−), or more than 2-fold higher than (+) the parental construct.
aCommon Gα numbering (CGN) system (Flock et al., 2015).
bNot applicable.
cNot determined.
dSubstitution of switch II residues 227–230 with two glycine residues.
eDeletion of switch III residues 255–264.
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designed to stabilise the region around switch III, through a poten-
tial interaction with Arg265. The G49D and E50N mutations,
which are located in the P-loop, were designed to reduce ﬂexibility
and conformationally constrain this region, through potential inter-
actions with Arg265 and Lys293, respectively. The sixth mutation
(L272D) was designed to conformationally constrain switch II,
through potential interactions with a cluster of charged and polar
residues (227–233) within its N-terminal region (Fig. 2b).
Thermostabilisation of the β1ARΔNC–mini-Gs complex
in detergent
The majority of mutations from the ﬁrst mutagenic screen did not
stabilise the β1AR–mini-Gs complex in detergent. We hypothesised
that this was because they did not speciﬁcally stabilise mini-Gs in it
receptor-bound conformation, therefore, a second panel of
approximately 150 mutants were designed with the intention of
stabilising the receptor-bound conformation of mini-Gs. This muta-
genic screen was based on the structure of the β2AR–Gs complex
(Rasmussen et al., 2011b), and focused on regions of Gαs that
undergo large conformational changes upon receptor binding.
Many of the mutations tested during this second screen were desta-
bilising to mini-Gs in its basal GDP-bound state, therefore they
could not be tested individually (i.e. in the mini-Gs161 parental
construct). Instead, they were added to mini-Gs199, which was
identical to mini-Gs183, except that it contained a modiﬁed linker
region (Supplementary Table SIII). This construct was very stable
in its basal GDP-bound state (72.5°C) and could thus negate the
destabilising effects of the additional mutations. Mini-Gs mutants
were screened in complex with detergent-solubilised β1ARΔNC
using the 3H-norepinephrine Tm assay. Four stabilising mutations
were identiﬁed (Table II), the best of which (I372A) increased the
apparent Tm of the complex from 29.2 to 34.0°C and it combined
additively with V375I, to give an apparent Tm of 35.0°C. This was
3.0°C higher than the β1ARΔNC–Nb80 complex and only 0.8°C
lower than the β1ARΔNC–Gs–Nb35 complex. The other mutations
did not combine additively with I372A and V375I and were
rejected (results not shown).
Both of the positive detergent-stabilising mutations were located
within the α1 or α5 helices. Alignment of Gαs in its receptor-bound
conformation (Rasmussen et al., 2011b) with the GTP-bound struc-
ture (Fig. 2c; Sunahara et al., 1997) identiﬁed an unfavourable steric
clash across the α1–α5 helix interface, involving residues Met60,
His64 (from the α1 helix) and Ile372 (from the α5 helix). This clash
was predicted to prevent close packing of the C-terminal region of
the α1 helix against the α5 helix and the core of the GαGTPase
domain, thus exposing the core of the protein to the solvent. The
I372A mutation was designed to eliminate this clash and facilitate
better packing in this region. Similarly, the V375I mutation was
designed to improve packing between the α5 helix and the core of
the protein in its receptor-bound conformation (Fig. 2d).
Validation of mini-Gs
The detergent-stabilised construct (mini-Gs345) was modiﬁed for
crystallographic applications by changing the linker and shortening
Table II. β1ARΔNC thermostability data
Binding partner Mutation CGN codea Apparent Tm of β1ARΔNC in DDM,
measured by 3H-NE binding (°C)
Stability of GDP-bound mini-
Gs measured by DSF (°C)
None n.a.b n.a. 25.9 ± 0.0 (n = 3) n.a.
Nb80 n.a. n.a. 32.0 ± 0.0 (n = 3) n.a.
Gs–Nb35 n.a. n.a. 35.8 ± 0.1 (n = 3) n.a.
Gαs n.a. n.a. n.d.c 50.1 ± 0.1 (n = 3)
Mini-Gs162 A249D 25.1 (n = 1) 60.6 ± 0.1 (n = 3)
Mini-Gs164 A249D, SIII
d 28.6 (n = 1) 66.5 ± 0.0 (n = 3)
Mini-Gs165 A249D, S252D, SIII 28.5 ± 0.2 (n = 2) 68.7 ± 0.0 (n = 3)
Mini-Gs169 A249D, S252D, SIII, L272D 28.8 (n = 1) 67.1 ± 0.0 (n = 3)
Mini-Gs183 G49D, E50N, A249D, S252D, SIII, L272D 28.7 ± 0.2 (n = 4) 72.5 ± 0.0 (n = 3)
Mini-Gs199
e G49D, E50N, A249D, S252D, SIII, L272D 29.2 ± 0.2 (n = 17) 72.5 ± 0.0 (n = 3)
Mini-Gs254 Mini-Gs199 +M60A 60
G.H1.8 31.5 ± 0.3 (n = 5) 70.3 ± 0.0 (n = 3)
Mini-Gs350 Mini-Gs199 + L63Y 63
G.H1.11 30.9 ± 0.4 (n = 2) 70.7 ± 0.0 (n = 3)
Mini-Gs340 Mini-Gs199 + I372A 372
G.H5.4 34.0 (n = 1) 66.6 ± 0.1 (n = 3)
Mini-Gs303 Mini-Gs199 + V375I 375
G.H5.7 31.5 ± 0.6 (n = 3) 70.3 ± 0.0 (n = 3)
Mini-Gs352 Mini-Gs199 + L63Y, I372A 34.5 (n = 1) 64.7 ± 0.1 (n = 3)
Mini-Gs345 Mini-Gs199 + I372A, V375I 35.0 (n = 1) 65.4 ± 0.1 (n = 3)
Mini-Gs393
f Final mini-Gs construct 34.1 ± 0.5 (n = 3) 65.3 ± 0.0 (n = 3)
Thermostability data for either detergent-solubilised β1ARΔNC complexes or mini-Gs mutants in the GDP-bound state. Apparent Tm values represent the
mean ± SEM from the number (n) of independent experiments performed in duplicate. Some apparent Tm values were determined from a single experiment, with
an assumed error of ±0.5°C. Apparent Tm values for mini-Gs in the GDP-bound state were determined by differential scanning ﬂuorimetry (Supplementary Fig.
S6).
aCommon Gα numbering (CGN) system (Flock et al., 2015).
bNot applicable.
cNot determined.
dDeletion of switch III residues 255–264 is referred to as SIII.
eMini-Gs199 contains the same mutations as mini-Gs183, but has a redesigned linker region (Supplementary Table SIII), and was used as the parental construct
for screening detergent-stabilising mutations.
fMini-Gs393 contains the same mutations as mini-Gs345, but has an additional truncation of the N-terminus and redesigned linker region (Supplementary
Table SIII), and was used as the starting construct for crystallisation trials.
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the N-terminus (Supplementary Table SIII). The ﬁnal stabilised con-
struct, mini-Gs393 (Supplementary Fig. S7 and S8), was able to elicit
an equal or greater shift in isoprenaline afﬁnity compared to either
Nb80 or Gs–Nb35 (Fig. 3a–c) whether the experiments were per-
formed using membrane-embedded β1ARΔNC (Ki of 4.1 ± 1.1 nM
compared to 5.8 ± 0.8 nM and 6.8 ± 0.6 nM, respectively),
membrane-embedded β1AR-84 (Ki of 3.6 ± 0.0 nM compared to
28 ± 1 nM and 16 ± 4 nM, respectively) or detergent-solubilised
β1AR-84 (Ki of 4.7 ± 0.4 nM compared to 83 ± 2 nM and
23 ± 7 nM, respectively). Crucially, for the mini-Gs393 complex,
high-afﬁnity isoprenaline binding was maintained when β1AR-84
was solubilised in detergent, and was 17-fold higher than that of the
Nb80 complex and 5-fold higher than that of the Gs–Nb35
complex. Thus mini-Gs393 is an ideal protein for the formation of
stable GPCR complexes in detergent solution.
The biochemical properties of mini-Gs393 also make it ideal for
structural studies of GPCR complexes. Mini-Gs393 was readily puri-
ﬁed to homogeneity with a yield of 100mg of puriﬁed protein per litre
of E. coli culture, and it could be concentrated to over 100mg/ml
(Supplementary Fig. S9). Analytical gel ﬁltration showed that mini-
Gs393 bound to puriﬁed β1ARΔNC in LMNG (Fig. 3d and e), dem-
onstrating that the complex could be puriﬁed in detergent. Recent
innovations in electron cryo-microscopy (cryo-EM; Bai et al., 2015)
suggest that large GPCR–G protein complexes could be amenable
for structure determination by single particle imaging. It is therefore
useful to note that mini-Gs399, a construct in which the N-terminal
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Fig. 2 Rational design of mutations to stabilise mini-Gs. (a) Structural alignment of Gαs (PDB code 1AZT; Sunahara et al., 1997), coloured magenta and grey, and
Arl2 (PDB code 1KSH; Hanzal-Bayer et al., 2002), coloured green. The Gαs GTPase domain aligns to Arl2 with an RMSD of 1.9 Å, despite sharing sequence iden-
tity of only 25%, determined using the Dali server (Holm and Rosenstrom, 2010). See Supplementary Fig. S4 for a sequence alignment between Gαs and Arl-2.
The inset shows an expanded view of mini-Gs residues (shown as sticks and underlined name) that were mutated (G49D, E50N, A249D, and S252D) to match
the corresponding residue in Arl2. Residues with which the mutations potentially interact are shown as sticks. (b) Mutation of Leu272, which is located within
the α3 helix of Gαs (PDB code 1AZT; Sunahara et al., 1997), to aspartic acid allows potential interactions with a cluster of charged and polar residues (227–233)
in the N-terminal region of switch II. (c) Alignment of Gαs in its GTP-bound conformation (PDB code 1AZT; Sunahara et al., 1997), coloured magenta, and GPCR-
bound conformation (PDB code 3SN6; Rasmussen et al., 2011b), coloured cyan. In the GPCR-bound conformation Ile372 (α5 helix) sterically clashes with Met60
and His64 (α1 helix), preventing close packing of the α1 helix against the core of the GαGTPase domain. (d) The V375I mutation (modelled using PyMOL) was
designed to increase hydrophobic contacts between the core of the GαGTPase domain and the α5 helix in its GPCR-bound conformation (PDB code 3SN6;
Rasmussen et al., 2011b). Residues that interact with Val375 are shown as sticks, additional contacts (less than 4.2 Å), which are predicted to be formed by the
δ-carbon (*) of the isoleucine mutation are displayed as dashed lines.
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residues 6–25 were replaced and the L272D mutation was reverted
to wild type (Supplementary Table SIII), retained its ability to form a
heterotrimer with Gβγ (Fig. 3f). The main advantage of the mini-
Gs399–Gβγ complex over heterotrimeric Gs, is that it lacks the GαAH
domain, which is highly dynamic in the GPCR-bound conformation
(Westﬁeld et al., 2011). Therefore GPCR complexes composed of
mini-Gs399–Gβγ are predicted to be more conformationally homo-
genous than those involving heterotrimeric Gs, and thus better suited
to cryo-EM applications.
Crystallisation of GPCRs often requires the use of short chain deter-
gents, so the thermostability of the β1ARΔNC–mini-Gs393 complex was
tested in four different detergents using the 3H-norepinephrine Tm assay
and compared to the analogous complexes with Nb80 and Gs–Nb35
(Fig. 3g and Supplementary Fig. S10). Under all conditions tested
uncoupled β1ARΔNC was signiﬁcantly less stable than when bound
to either mini-Gs393, Nb80 or Gs–Nb35. Similarly, β1ARΔNC was
always more stable bound to mini-Gs393 compared to Nb80.
β1ARΔNC–mini-Gs393 complexes were also considerably more
stable than β1ARΔNC–Gs–Nb35 complexes in short chain detergents,
although the later was marginally more stable in DDM. The striking
improvement in the thermostability by 5–8°C of the β1ARΔNC–mini-
Gs393 complex in NG and OG in comparison to other complexes
suggests it has signiﬁcant advantages for the structure determination
of receptors in the active state.
(f)
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Fig. 3 Validation of mini-Gs (a–c) A competition binding assay was used to measure the change in afﬁnity (Ki) of isoprenaline induced by Nb80, Gs–Nb35, or
mini-Gs393 coupling to: (a) membrane-embedded β1ARΔNC, (b) membrane-embedded β1AR-84 and (c) DDM-solubilised β1AR-84. (d) Analytical gel ﬁltration ana-
lysis of β1ARΔNC binding to mini-Gs393. The apparent molecular weight of mini-Gs393 was 23 kDa (17.1ml), which compares well with the theoretical value of
27 kDa. The apparent molecular weight of β1ARΔNC was 139 kDa (13.2ml), which is consistent with the 45 kDa receptor being associated with a large detergent
micelle; the shoulder at 11ml (> 300 kDa) probably represents aggregated receptor. A mixture of β1ARΔNC and mini-Gs393 (1.2-fold molar excess) resolved as a
predominant peak with an apparent molecular weight of 160 kDa (12.9ml). The 21 kDa increase in the apparent molecular weight of the β1ARΔNC–mini-Gs393
complex compared to uncoupled β1ARΔNC is consistent with mini-Gs393 binding with 1:1 stoichiometry. (e) SDS-PAGE analysis of the gel ﬁltration eluate con-
ﬁrmed the presence of both β1ARΔNC and mini-Gs393 in the peak fractions. (f) Analytical gel ﬁltration analysis of Gβγ binding to mini-Gs399. The apparent
molecular weights of mini-Gs399 (Supplementary Table SIII) and Gβγ were 32 kDa (16.4ml) and 42 kDa (15.8ml), respectively, which is in close agreement with
the theoretical values of 29 kDa and 46 kDa, respectively. An equimolar mixture of mini-Gs399 and Gβγ resolved as a single peak with an apparent molecular
weight of 73 kDa (14.6ml). The 31 kDa increase in the apparent molecular weight of the mini-Gs399–Gβγ complex compared to Gβγ is consistent with mini-Gs399
binding with 1:1 stoichiometry. (g) Thermostability of detergent-solubilised β1ARΔNC alone or in complex with Nb80, Gs–Nb35, or mini-Gs393, in different deter-
gents (Supplementary Fig. S10). Uncoupled β1ARΔNC did not survive solubilisation in NG or OG. Colours correspond to those used in (a). (h–i) GTP-mediated dis-
sociation of β1AR-84 complexes, measured by competition binding assay. The response in isoprenaline Ki induced by Gs, mini-Gs404 (Supplementary
Table SIII), or mini-Gs393 coupling to β1AR-84 was measured in the presence or absence of GTPγS (250 μM). (a–c,h,i) Data are representative of at least two inde-
pendent experiments, each performed in duplicate, with error bars ± SEM. (g) Data represent mean ± SEM of at least two independent experiments, each per-
formed in duplicate.
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The nucleotide-binding properties of the mutants were not exten-
sively studied in this work, but one interesting observation was that
the β1AR-84–mini-Gs393 complex was resistant to dissociation by
physiological concentrations of GTP (Fig. 3h and i). GTPγS fully
reversed the shift in Ki induced by Gs binding to β1AR-84 from
271 ± 54 nM to 2.7 ± 0.1 μM. The shift in isoprenaline Ki induced
by mini-Gs404 (an identical construct to mini-Gs393, except that the
I372A and V375I mutations were reverted to wild type;
Supplementary Table SIII) binding to β1AR-84 was almost fully
reversed by GTPγS (from 18 ± 2 nM to 700 ± 60 nM). However,
there was no signiﬁcant difference in the isoprenaline Ki of the
β1AR-84–mini-Gs393 complex in either the presence or absence of
GTPγS (3.6 ± 0.0 nM compared to 5.2 ± 0.7 nM; P = 0.137). This
unresponsiveness to GTPγS was caused by the I372A mutation (see
Discussion), because mini-Gs391 (an identical construct to mini-
Gs393, except that only the V375I mutation was reverted to wild
type; Supplementary Table SIII), behaved in a similar fashion to
mini-Gs393 (Supplementary Fig. S11). Unresponsiveness to GTP is a
useful property that should allow the formation of stable GPCR–
mini-Gs complexes in vivo, which may be a novel method to
improve expression and puriﬁcation of unstable GPCRs.
Discussion
Several novel approaches have been developed to stabilise and crys-
tallise GPCRs in their active conformation, including complexation
with G protein-derived peptides (Scheerer et al., 2008), G protein-
mimicking nanobodies (Huang et al., 2015; Kruse et al., 2013;
Rasmussen et al., 2011a; Ring et al., 2013) and a nanobody-
stabilised heterotrimeric G protein (Rasmussen et al., 2011b). All of
these complexes appear to stabilize the receptor in its active state,
which is characterised by an outward movement of helix 6 and con-
served conformational changes of residues within the core of the
receptor, particularly R3.50, Y5.58 and Y7.53 (Huang et al., 2015).
The β2AR–Gs complex provided the ﬁrst insight into the organisa-
tion of the native GPCR–G protein interface, which is something
that other binding proteins cannot recreate, but frustratingly, com-
plexes involving heterotrimeric Gs are also the most difﬁcult to crys-
tallise, due to their large size and dynamic nature. Therefore, we
designed a minimal G protein that offers signiﬁcant advantages to
the crystallisation of native-like GPCR–G protein complexes, specif-
ically mini-Gs is a small, soluble, highly expressed protein, which
readily forms a detergent-stable complex with GPCRs.
Our lab has previously determined the structures of both β1AR
and the adenosine A2A receptor (A2AR) bound to agonists (Lebon
et al., 2011b; Warne et al., 2011), and therefore crystallisation trials
were conducted for both β1AR and A2AR in complex with mini-Gs,
employing a parallel approach of lipidic cubic phase (LCP) and
vapour diffusion. Crystals were obtained quickly for wild type A2AR
in complex with mini-Gs by vapour diffusion in the detergent
octylthioglucoside (OTG), and we were able to solve the structure to
3.4 Å resolution (Carpenter et al., 2016). β1AR crystallisation trials
are still at an early stage, and have not yet yielded crystals that dif-
fract to sufﬁcient resolution for structure determination. The
molecular organisation of A2AR–mini-Gs is remarkably similar to
that of the β2AR–Gs complex (Rasmussen et al., 2011b), with A2AR
adopting a conformation that closely resembles Gs-bound β2AR. In
addition, mini-Gs bound to A2AR is very similar to the analogous
region in Gs bound to β2AR (Rmsd 0.9 Å; Carpenter et al., 2016).
Thus mini G proteins are useful surrogates for heterotrimeric G pro-
teins to stabilise and determine structures of GPCRs in their active
conformation. However, it must be appreciated that GPCRs have
not evolved to be stable in the activated state bound to a G protein,
but instead have evolved to be unstable so that signalling lasts for
short, deﬁned, periods of time before being terminated. Therefore,
additional approaches, such as thermostabilisation of the GPCR
(Tate, 2012) bound to mini-Gs, may be required before the struc-
tures of many complexes can be determined. The high-level expres-
sion and stability of mini-Gs makes this a trivial undertaking
compared to using the wild type heterotrimeric G protein. It is also
important to note that further modiﬁcations of mini-Gs, such as
deletions and mutations, may be required to facilitate crystallisation
of different GPCRs. The crystal structure of the A2AR–mini-Gs com-
plex was solved using mini-Gs414, which is identical to mini-Gs393
except that it contains the additional mutation L63Y (Table II).
Well diffracting crystals of the A2AR–mini-Gs complex were grown
using either mini-Gs393 or mini-Gs414, however, the A2AR–mini-
Gs414 complex produced a different crystal form that diffracted to
slightly better resolution, and was thus used for structure determin-
ation. There was no discernible difference between these two com-
plexes in either the competition binding assay or thermostability
assay (results not shown), suggesting that the main effect of the
L63Y mutation was on crystallogenesis.
The development of mini-Gs involved extensive screening to
identify key deletions and point mutations that improved both the
conformational homogeneity and thermostability of the β1AR–mini-
Gs complex (Fig. 4). Deletion of the GαAH domain, which is the
most dynamic region of Gs in its GPCR-bound conformation, sig-
niﬁcantly reduced the conformational heterogeneity in the β1AR–
mini-Gs complex. This deletion also eliminated the requirement of
Gβγ subunits for GPCR coupling, removing the need for exogenous
components, such as Nb35, to stabilise the Gα–Gβγ interface. In the
absence of Gβγ subunits the N-terminus of mini-Gs could be par-
tially deleted, resulting in a more compact protein. The switch III
GαGTPase
GαAH Switch III
Gβ1
Gγ2  G49D / E50N
A249D / S252D
I372A / V375I
L272D
N-terminal helixα5 helix
GDP
Fig. 4 A model of heterotrimeric Gs highlighting the region that corresponds
to mini-Gs (magenta). The model of heterotrimeric Gs was constructed by
superposition of the crystal structures of Gαs (PDB code 1AZT; Sunahara
et al., 1997) and heterotrimeric Gαt/i1 (PDB code 1GOT; Lambright et al.,
1996). Residues that were mutated in mini-Gs (shown as spheres) were clus-
tered in three regions of the protein: the nucleotide-binding pocket (green),
switch II (blue), and the α5 helix (yellow). Regions of Gαs that were deleted in
mini-Gs (GαAH, switch III and half of the N-terminal helix) are coloured grey.
The Gβγ subunits, which are not required for mini-Gs coupling to GPCRs are
shown as ribbons and coloured grey. GDP is shown as sticks and coloured
orange.
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deletion removed a dynamic region of mini-Gs, replacing it with
deﬁned secondary structure components, and resulted in a signiﬁ-
cant improvement in the thermostability of the complex. A total of
seven point mutations were required to fully stabilise mini-Gs in
complex with β1AR (Fig. 4). Extensive mutagenic screens were
employed that targeted most regions of mini-Gs, however, all of the
mutations utilised in the ﬁnal construct were clustered around three
regions of the protein (nucleotide-binding pocket, switch II, and α5
helix). The G49D, E50N, A249D and S252D mutations were
designed to stabilise the nucleotide-binding pocket and P-loop
(Fig. 2a), and all of these mutations improved the thermostability of
both the basal GDP-bound state of mini-Gs and the β1AR–mini-Gs
complex. The L272D mutation, which was located adjacent to
switch II, was designed to conformationally constrain this ﬂexible
region (Fig. 2b), and resulted in improved thermostability of the
β1AR–mini-Gs complex. The I372A and V375I mutations, which
were located in the α5 helix, were designed to improve packing
between the core of protein and the α1 or α5 helices, respectively
(Fig. 2c and d). These two mutations speciﬁcally improved the ther-
mostability of the β1AR–mini-Gs complex in detergent. None of
these mutations were located within the receptor-binding site, ensur-
ing that the native GPCR–G protein interface was maintained, and
allowing mini-Gs to be co-crystallised with other Gs-coupled recep-
tors. During the course of this work the I372A mutation was also
independently reported to stabilise a complex between rhodopsin
and the adenylate cyclase inhibiting G protein Gi1 (Sun et al., 2015).
The G protein engineering work has also provided insight into the
mechanism of G protein activation. Binding of Gαs to β2AR triggers
displacement of the G protein α5 helix to a position that is predicted
to sterically clash with the α1 helix. This unfavourable clash appears
to prevent close packing of the C-terminal region of the α1 helix
against the α5 helix and the core of the GTPase domain (Fig. 2c), and
this region is indeed disordered in the β2AR–Gs complex (Rasmussen
et al., 2011b). The α1 helix forms part of the nucleotide-binding
pocket and directly connects to the P-loop (Fig. 2c), which is the main
determinant of nucleotide binding afﬁnity in G proteins (John et al.,
1990). Destabilisation of the α1 helix has previously been suggested
to be a key event in receptor-mediated nucleotide exchange (Flock
et al., 2015; Kaya et al., 2014; Sun et al., 2015), however the mechan-
ism of this destabilisation was unclear. Here, we identiﬁed a potential
steric clash between Ile372 from the α5 helix and residues from the
α1 helix (in particular Met60), which appears to play an important
role in this nucleotide exchange. Mutation of Ile372 to alanine, which
was predicted to eliminate the steric clash, was shown to inhibit GTP-
mediated dissociation of the β1AR–mini-Gs complex. These data indi-
cate that, in Gs, Ile372 acts as a relay between the GPCR-binding site
(α5 helix) and the key regions of the nucleotide-binding pocket (α1
helix and P-loop), allowing the receptor to allosterically destabilise
the nucleotide-binding pocket and modulate nucleotide exchange. We
suggest that the I372A mutation uncouples GPCR binding from occu-
pancy of the nucleotide-binding pocket, a hypothesis that was supported
by the presence of GDP in one of the two copies of mini-Gs in the asym-
metric unit of the A2AR–mini-Gs structure (Carpenter et al., 2016).
Mini G proteins are novel tools that have many potential appli-
cations, including characterisation of receptor pharmacology in
response to different classes of agonists (full, partial and weak),
binding afﬁnity and kinetic studies, thermostabilisation of GPCRs in
their active conformation, drug discovery, and structure determin-
ation of native-like GPCR–G protein complexes. Furthermore, all of
the mutations reported here are located within conserved regions of
the Gα subunit. Therefore, the concept is potentially transferable to
all classes of heterotrimeric G proteins, which would allow the pro-
duction of a panel of mini G proteins capable of coupling any
GPCR.
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